日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study

一项针对不适合接受经导管动脉化疗栓塞术(TACE)且肿瘤负荷超过“Up-To-7”标准的中晚期肝细胞癌患者的阿特珠单抗联合贝伐珠单抗治疗的II期研究的主要分析:REPLACEMENT研究

Kudo, Masatoshi; Ueshima, Kazuomi; Tsuchiya, Kaoru; Yamashita, Tatsuya; Shimose, Shigeo; Numata, Kazushi; Kodama, Yuzo; Itoh, Shinji; Tanaka, Yasuhito; Kuroda, Hidekatsu; Aikata, Hiroshi; Hiraoka, Atsushi; Moriguchi, Michihisa; Tateishi, Ryosuke; Ogasawara, Sadahisa; Yamamoto, Kouji; Ikeda, Masafumi

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B

阿特珠单抗联合贝伐珠单抗治疗Child-Pugh B级肝细胞癌患者的疗效和安全性

Sasaki, Ryu; Shimose, Shigeo; Saeki, Issei; Ito, Takanori; Takeuchi, Yasuto; Tani, Joji; Tomonari, Tetsu; Sasaki, Kyo; Kakizaki, Satoru; Hatanaka, Takeshi; Miuma, Satoshi; Shirono, Tomotake; Iwamoto, Hideki; Tanabe, Norikazu; Yamamoto, Takafumi; Kanayama, Yuki; Naganuma, Atsushi; Nishina, Sohji; Takayama, Tetsuji; Kobara, Hideki; Otsuka, Motoyuki; Kawashima, Hiroki; Takami, Taro; Kawaguchi, Takumi; Miyaaki, Hisamitsu

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

阿特珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌患者后序贯免疫检查点抑制剂再治疗的疗效

Ito, Takanori; Shimose, Shigeo; Saeki, Issei; Takeuchi, Yasuto; Tani, Joji; Tomonari, Tetsu; Sasaki, Ryu; Sasaki, Kyo; Kakizaki, Satoru; Hatanaka, Takeshi; Iwamoto, Hideki; Tanabe, Norikazu; Yamamoto, Takafumi; Naganuma, Atsushi; Shirono, Tomotake; Kanayama, Yuki; Miyaaki, Hisamitsu; Nishina, Sohji; Takayama, Tetsuji; Kobara, Hideki; Otsuka, Motoyuki; Takami, Taro; Kawaguchi, Takumi; Kawashima, Hiroki

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR)

对 Pola-R-CHP 治疗未经治疗的日本 DLBCL 患者的多中心研究(POLASTAR)的初步分析

Satake, Atsushi; Nagate, Yasuhiro; Miyawaki, Kohta; Fujiwara, Yuki; Ota, Shuichi; Muta, Tsuyoshi; Rai, Shinya; Tsurumi, Hisashi; Suzuki, Ritsuro; Miyake, Takaaki; Goto, Hideki; Fukuhara, Noriko; Sakata-Yanagimoto, Mamiko; Izutsu, Koji; Nishikori, Momoko; Shibayama, Hirohiko; Kumode, Takahiro; Ennishi, Daisuke; Shimose, Takayuki; Inubashiri, Naoki; Matsumura, Itaru; Akashi, Koichi; Kato, Koji

Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib

在化疗多样化时代,肝细胞癌的策略性药物序贯治疗:最大化乐伐替尼的治疗获益

Iwamoto, Hideki; Shimose, Shigeo; Koga, Hironori; Kawaguchi, Takumi

Single Photocatalytic Hydrosilylation of Alkenes for the Synthesis of Bis(silyl) and Silaboryl Alkanes

烯烃单光催化氢硅化反应合成双(硅基)烷烃和硅硼基烷烃

Nagashima, Yuki; Suzuki, Mone; Shimose, Asuha; Arai, Ryo; Tanaka, Ken; Uchiyama, Masanobu

Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED)

铂类药物联合依托泊苷和度伐利尤单抗治疗伴有未治疗脑转移的广泛期小细胞肺癌:一项多中心、单臂 II 期试验(LOGiK2001、SPEED)

Shiraishi, Y; Shimose, T; Tsuchiya-Kawano, Y; Ishii, H; Mizuno, K; Toi, Y; Daga, H; Ito, K; Iyama, S; Taniguchi, H; Morinaga, R; Harada, T; Inoue, H; Misumi, Y; Naoki, K; Tobino, K; Izumi, M; Omori, S; Tsumura, S; Yamanaka, Y; Sakata, Y; Miura, S; Mizutani, H; Oki, M; Iwama, E; Otsubo, K; Okamoto, I

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy

癌症恶病质对PD-L1肿瘤比例评分≥50%的非小细胞肺癌患者接受帕博利珠单抗单药治疗与免疫检查点抑制剂联合化疗治疗预后的临床影响

Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Kijima, Takashi; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Shimose, Takayuki; Takayama, Koichi

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿特珠单抗联合贝伐珠单抗治疗不适合经TACE治疗且超出Up-To-7标准的中晚期肝细胞癌:REPLACEMENT研究的最终分析

Ueshima, Kazuomi; Tsuchiya, Kaoru; Yamashita, Tatsuya; Shimose, Shigeo; Numata, Kazushi; Kodama, Yuzo; Itoh, Shinji; Tanaka, Yasuhito; Kuroda, Hidekatsu; Ohkawa, Kazuyoshi; Kuzuya, Teiji; Ikeda, Masafumi; Kooka, Youhei; Aikata, Hiroshi; Hiraoka, Atsushi; Moriguchi, Michihisa; Tateishi, Ryosuke; Ogasawara, Sadahisa; Yamamoto, Kouji; Kudo, Masatoshi

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)

Turtle 研究:一项针对老年广泛期小细胞肺癌患者的 Durvalumab 联合卡铂和依托泊苷的 II 期研究 (LOGiK 2003)

Ishii, Hidenobu; Azuma, Koichi; Yamanaka, Yuta; Yoshioka, Hiroshige; Toi, Yukihiro; Shingu, Naoki; Naoki, Katsuhiko; Okamoto, Masaki; Tsuchiya-Kawano, Yuko; Harada, Taishi; Inoue, Hiroyuki; Ishii, Hiroshi; Tobino, Kazunori; Nakashima, Chiho; Koreeda, Yoshifusa; Hisamatsu, Yasushi; Tsumura, Shinsuke; Inagaki, Takashi; Mizuno, Keiko; Shimose, Takayuki; Okamoto, Isamu